Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial
Yuan Li(Sun Yat-sen University), Hai‐Qiang Mai(Sun Yat-sen University)
Cited by 45
Related Papers
EBV infection-induced GPX4 promotes chemoresistance and tumor progression in nasopharyngeal carcinoma
|Cell Death and Differentiation|2022|148